Could a common supplement help rare lung disease?
NCT ID NCT05593588
First seen Jun 26, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This phase 2 trial tests whether the supplement fisetin can improve lung disease in people with common variable immunodeficiency (CVID). Twenty participants will receive either fisetin or a placebo on four days over a month. The study measures changes in immune cells and lung function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Fisetin (a plant-based supplement)
- What this could lead to
- If it works, this could point toward a new treatment for lung scarring in people with CVID.
- What could go wrong
- This is a small early-phase trial with only 20 participants, so results may not apply widely. Fisetin is a supplement and may not be strong enough to change the disease course.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMMON VARIABLE IMMUNODEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple questionnaire spot how rheumatic lung disease affects daily life?
- New IVIG aims to slash infection risk for immune-deficient patients
- Breathing test could help doctors personalize antibody therapy for immune deficiency
- Gentler transplant shows promise for kids with blood diseases
- Can a simple ultrasound spot hidden liver danger in immune disorder patients?
- Can a new immune system fix T-Cell diseases? trial tests donor transplants